<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53796">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100631</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-VC-200-005</org_study_id>
    <nct_id>NCT02100631</nct_id>
  </id_info>
  <brief_title>A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults</brief_title>
  <official_title>A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PaxVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PaxVax, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate that the vaccine offers protection based on antibody levels in older adults and
      is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Seroconversion by vibriocidal antibody (i.e., a 4-fold rise over baseline titer)</measure>
    <time_frame>up to 28 days following vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of vaccinees with at least a 4-fold rise vibriocidal antibody</measure>
    <time_frame>up to 180 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with serious and non serious adverse events</measure>
    <time_frame>following vaccination through 180 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cholera</condition>
  <arm_group>
    <arm_group_label>PXVX0200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; &gt; 2x108 CFU in a liquid suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200</intervention_name>
    <arm_group_label>PXVX0200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men or women,

          -  age 46 to 64 years inclusive;

          -  normal medical history and physical examination

          -  Women must have a negative pregnancy test

        Exclusion Criteria:

          -  travel to a cholera endemic area in the previous 5 years;

               -  abnormal stool pattern or regular use of laxatives;

               -  Currently active unstable or undiagnosed medical conditions

               -  current or recent antibiotic use;

               -  pregnancy or nursing;

               -  Previously received a licensed or investigational cholera vaccine

               -  History of cholera or enterotoxigenic E. coli infection

               -  History of Guillain-Barr√© Syndrome

               -  Received or plans to receive any other licensed vaccines, except for seasonal
                  influenza

               -  Recipient of bone marrow or solid organ transplant

               -  Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative
                  disorders diagnosed or treated during the past 5 years

               -  Use of systemic chemotherapy in the previous 5 years prior to the study

               -  any immunosuppressive medical condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Studdard, MD</last_name>
      <phone>251-414-1984</phone>
    </contact>
    <investigator>
      <last_name>Harry Studdard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avail Clinical</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hill, MD</last_name>
      <phone>386-785-2183</phone>
    </contact>
    <investigator>
      <last_name>John Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Feldman, MD</last_name>
      <phone>305-667-4511</phone>
    </contact>
    <investigator>
      <last_name>Robert Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaac Marcadis, MD</last_name>
      <phone>561-689-0606</phone>
    </contact>
    <investigator>
      <last_name>Isaac Marcadis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Anderson, MD</last_name>
      <phone>404-727-1746</phone>
    </contact>
    <investigator>
      <last_name>Evan Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Johnson, MD</last_name>
      <phone>913-825-4400</phone>
    </contact>
    <investigator>
      <last_name>Casey Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Research</name>
      <address>
        <city>Witchita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Klein, MD</last_name>
      <phone>316-689-6629</phone>
    </contact>
    <investigator>
      <last_name>Terry Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greenberg, MD</last_name>
      <phone>859-323-6327</phone>
    </contact>
    <investigator>
      <last_name>Richard Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Borders, MD</last_name>
      <phone>859-278-5926</phone>
      <phone_ext>209</phone_ext>
    </contact>
    <investigator>
      <last_name>James Borders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Barnett, MD</last_name>
      <phone>617-414-3623</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ervin, MD</last_name>
      <phone>816-943-0770</phone>
    </contact>
    <investigator>
      <last_name>John Ervin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Gorse, MD</last_name>
      <phone>314-977-5500</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey Gorse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Strout, MD</last_name>
      <phone>843-856-3784</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Strout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Kapusta, MD</last_name>
      <phone>972-241-1222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Richardson, MD</last_name>
      <phone>801-261-2000</phone>
    </contact>
    <investigator>
      <last_name>Stephen Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beth Kirkpatrick, MD</last_name>
      <phone>802-656-5288</phone>
    </contact>
    <investigator>
      <last_name>Beth Kirkpatrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
